查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非囊性纖維化支氣管擴張市場：全球市場規模、佔有率、趨勢分析、機會、預測報告，2019-2029
市場調查報告書
商品編碼
1334470

非囊性纖維化支氣管擴張市場：全球市場規模、佔有率、趨勢分析、機會、預測報告，2019-2029

Non-cystic Fibrosis Bronchiectasis Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Treatment ; By Type ; By Diagnosis ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到2029年，全球非囊性纖維化支氣管擴張市場規模將達到13億美元。

全球非囊性纖維化支氣管擴張症市場的推動因素包括非囊性纖維化支氣管擴張症患病率上升、全球人口快速高齡化和呼吸系統疾病的高易感性以及診斷技術的不斷進步。由於技術的進步，該疾病蓬勃發展。 ，提高認知和早期診斷工作。

領先的戰略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，到2022年，非囊性纖維化支氣管擴張症的全球市場規模將達到 9.4 億美元。 BlueWeave表示，在2023-2029年的預測期內，全球非囊性纖維化支氣管擴張症市場規模預計將以5.55%的年複合成長率成長，並於2029年達到12.98億美元。全球非囊性纖維化支氣管擴張市場的主要成長促進因素包括慢性病患病率的增加、醫療保健支出的增加以及政府舉措的增加。治療方案的進步以及公眾和醫療保健專業人員對支氣管擴張症狀認知的提高，導致了早期診斷和患者管理的改善。市場成長也受到醫療保健支出增加的顯著影響，特別是在新興經濟體，這改善支氣管擴張患者獲得診斷和治療的機會。不斷增加的研發活動和新興市場提供的潛在機會預計將在預測期內進一步推動市場開拓。然而，治療選擇有限、缺乏針對特異性疾病的治療、疾病管理和患者依從性方面的課題、高昂的治療成本和醫療保健負擔預計將限制分析期間的整體市場成長。

本報告的詳細分析提供了有關全球非囊性纖維化支氣管擴張市場的成長潛力、未來趨勢和統計資料的資訊。還涵蓋了推動市場總規模預測的要素。本報告承諾提供全球非囊性纖維化支氣管擴張市場的最新技術趨勢以及行業見解，以幫助決策者做出明智的戰略決策。此外還分析了市場的成長促進因素、課題和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球非囊性纖維化支氣管擴張市場洞察

  • 行業價值鏈分析
  • DROC分析
    • 成長動力
      • 非囊性纖維化支氣管擴張的患病率增加
      • 人口高齡化，呼吸道疾病高罹患率
      • 診斷技術的進步
      • 努力提高認知和早期診斷
    • 抑制因素
      • 治療選擇有限且缺乏針對疾病的特異性治療
      • 疾病管理和患者依從性方面的課題
      • 高昂的治療費用和醫療負擔
    • 機會
      • 對個人化醫療和精準治療方法的需求不斷成長
      • 醫療保健成本上升和基礎設施發展
    • 課題
      • 複雜疾病的病理學和異質性
      • 臨床管理指南缺乏共識
  • 技術進步/最新發展
  • 法律規範
  • 波特五力分析

第4章 全球非囊性纖維化支氣管擴張市場概述

  • 2019-2029年市場規模和金額預測
    • 按金額
  • 市場佔有率及預測
    • 按治療
      • 外科手術
      • 物理療法
      • 疫苗接種
      • 氣道藥物
      • 抗生素
      • 其他
    • 按類型
      • 靜脈
      • 口服
      • 其他
    • 按診斷
      • CT掃描
      • 支氣管鏡檢查
      • 胸部X光檢查
      • 肺功能
      • 痰培養測試
      • 驗血
      • 其他
    • 按最終用戶
      • 診所
      • 醫院
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美非囊性纖維化支氣管擴張市場

  • 2019-2029年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按治療
    • 按類型
    • 按診斷
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲非囊性纖維化支氣管擴張市場

  • 2019-2029年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按治療
    • 按類型
    • 按診斷
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 荷蘭
      • 其他歐洲國家

第7章 亞太非囊性纖維化支氣管擴張市場

  • 2019-2029年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按治療
    • 按類型
    • 按診斷
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 菲律賓
      • 越南
      • 亞太地區其他國家

第8章 拉丁美洲非囊性纖維化支氣管擴張市場

  • 2019-2029年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按治療
    • 按類型
    • 按診斷
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 哥倫比亞
      • 拉丁美洲其他地區

第9章 中東和非洲非囊性纖維化支氣管擴張市場

  • 2019-2029年市場規模和金額預測
    • 按金額
  • 市場佔有率及預測
    • 按治療
    • 按類型
    • 按診斷
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第10章 競爭形勢

  • 主要企業及其產品列表
  • 2022年全球非囊性纖維化支氣管擴張公司市場佔有率分析
  • 按管理參數進行競爭基準測試
  • 主要戰略發展（合併、收購、合作夥伴關係等）

第11章 COVID-19 對全球非囊性纖維化支氣管擴張市場的影響

第12章 公司簡介（公司簡介、財務矩陣、競爭形勢、關鍵人才、主要競爭、聯繫地址、戰略展望和SWOT分析）

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • Insmed Incorporated
  • Bayer AG
  • Other Prominent Players

第13章 關鍵戰略建議

第14章 調查方法

簡介目錄
Product Code: BWC23655

Global Non-cystic Fibrosis Bronchiectasis Market Size Set to Touch USD 1.3 Billion by 2029.

Global non-cystic fibrosis bronchiectasis market is flourishing because of the rising prevalence of non-cystic fibrosis bronchiectasis, rapidly aging world population and its higher susceptibility to respiratory diseases, ongoing advancements in diagnostic technologies, and growing awareness and early diagnosis initiatives.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global non-cystic fibrosis bronchiectasis market size at USD 0.94 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global non-cystic fibrosis bronchiectasis market size to grow at a CAGR of 5.55% reaching a value of USD 1.298 billion by 2029. Major growth drivers for the global non-cystic fibrosis bronchiectasis market include an increasing prevalence of chronic diseases, coupled with a rising healthcare expenditure and growing government initiatives. Advancements in treatment options and growing awareness among the general population and healthcare professionals about bronchiectasis symptoms have led to early diagnosis and improved patient management. Also, the market's growth is notably influenced by rising healthcare spending, particularly in emerging economies, which has facilitated better access to diagnosis and treatment for bronchiectasis patients. The rise in research and development activities and the potential opportunities presented by emerging markets are expected to further propel the market's development during the forecast period. However, limited treatment options and lack of disease-specific therapies, challenges in disease management and patient adherence, and the high cost of treatment and healthcare burden are anticipated to restrain the overall market growth during the period in analysis.

Global Non-cystic Fibrosis Bronchiectasis Market - Overview:

The global non-cystic fibrosis bronchiectasis market refers to the worldwide industry involved in the diagnosis, treatment, and management of non-cystic fibrosis bronchiectasis, a chronic respiratory condition. Bronchiectasis is characterized by permanent dilation of the bronchi, leading to recurrent respiratory infections and impaired lung function. Unlike cystic fibrosis-related bronchiectasis, non-cystic fibrosis bronchiectasis is not caused by the genetic disorder cystic fibrosis. The market encompasses various healthcare stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions, all contributing to the development of innovative therapies, medications, and diagnostic tools to address the challenges posed by non-cystic fibrosis bronchiectasis and improve patients' quality of life.

Impact of COVID-19 on Global Non-cystic Fibrosis Bronchiectasis Market:

COVID-19 pandemic adversely affected the global non-cystic fibrosis bronchiectasis market. During the pandemic, healthcare systems were overwhelmed with managing COVID-19 patients, leading to a reduced focus on non-emergency conditions like bronchiectasis. Patients with respiratory conditions faced challenges in accessing healthcare facilities and adhering to treatment regimens due to restrictions and safety concerns. Also, disruptions in the supply chain and clinical trials affected the availability of treatments and research activities. However, with the gradual containment of the pandemic, the market is expected to recover as healthcare systems restore non-emergency services, and efforts to improve respiratory care continue.

Global Non-cystic Fibrosis Bronchiectasis Market - By End User:

On the basis of end user, the global non-cystic fibrosis bronchiectasis market is bifurcated into Clinic and Hospital segments. The hospital segment held a higher market share by end-users. Hospitals are major healthcare centers where patients with respiratory conditions like non-cystic fibrosis bronchiectasis often seek diagnosis, treatment, and management. Hospitals typically have advanced medical facilities, equipment, and specialized healthcare professionals, making them capable of providing comprehensive care for bronchiectasis patients. Also, non-cystic fibrosis bronchiectasis may require specialized diagnostic tests and treatments, such as CT scans, bronchoscopies, and lung function tests, which are readily available in hospitals. The hospital setting also allows for closer monitoring of patients and immediate intervention in case of complications.

Competitive Landscape:

Major players operating in the global non-cystic fibrosis bronchiectasis market include: Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals Inc., Insmed Incorporated, and Bayer AG. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-cystic Fibrosis Bronchiectasis Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Non-cystic Fibrosis Bronchiectasis Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Non-cystic Fibrosis Bronchiectasis Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Prevalence of Non-Cystic Fibrosis Bronchiectasis
      • 3.2.1.2. Aging Population and Higher Susceptibility to Respiratory Diseases
      • 3.2.1.3. Advancements in Diagnostic Technologies
      • 3.2.1.4. Growing Awareness and Early Diagnosis Initiatives
    • 3.2.2. Restraints
      • 3.2.2.1. Limited Treatment Options and Lack of Disease-Specific Therapies
      • 3.2.2.2. Challenges in Disease Management and Patient Adherence
      • 3.2.2.3. High Cost of Treatment and Healthcare Burden
    • 3.2.3. Opportunities
      • 3.2.3.1. Rising Demand for Personalized Medicine and Precision Treatment Approaches
      • 3.2.3.2. Increasing Healthcare Expenditure and Infrastructure Development
    • 3.2.4. Challenges
      • 3.2.4.1. Complex Disease Pathophysiology and Heterogeneity
      • 3.2.4.2. Lack of Consensus on Clinical Management Guidelines
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Non-cystic Fibrosis Bronchiectasis Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment
      • 4.2.1.1. Surgery
      • 4.2.1.2. Physiotherapy
      • 4.2.1.3. Vaccination
      • 4.2.1.4. Airway Pharmacotherapy
      • 4.2.1.5. Antibiotics
      • 4.2.1.6. Others
    • 4.2.2. By Type
      • 4.2.2.1. Intravenous
      • 4.2.2.2. Oral
      • 4.2.2.3. Others
    • 4.2.3. By Diagnosis
      • 4.2.3.1. CT scan
      • 4.2.3.2. Bronchoscopy
      • 4.2.3.3. Chest X-Ray
      • 4.2.3.4. Lung Function
      • 4.2.3.5. Sputum Culture Test
      • 4.2.3.6. Blood Tests
      • 4.2.3.7. Others
    • 4.2.4. By End User
      • 4.2.4.1. Clinic
      • 4.2.4.2. Hospital
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Non-cystic Fibrosis Bronchiectasis Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment
    • 5.2.2. By Type
    • 5.2.3. By Diagnosis
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Treatment
      • 5.2.5.1.2. By Type
      • 5.2.5.1.3. By Diagnosis
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Treatment
      • 5.2.5.2.2. By Type
      • 5.2.5.2.3. By Diagnosis
      • 5.2.5.2.4. By End User

6. Europe Non-cystic Fibrosis Bronchiectasis Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Type
    • 6.2.3. By Diagnosis
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Treatment
      • 6.2.5.1.2. By Type
      • 6.2.5.1.3. By Diagnosis
      • 6.2.5.1.4. By End User
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Treatment
      • 6.2.5.2.2. By Type
      • 6.2.5.2.3. By Diagnosis
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Treatment
      • 6.2.5.3.2. By Type
      • 6.2.5.3.3. By Diagnosis
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Treatment
      • 6.2.5.4.2. By Type
      • 6.2.5.4.3. By Diagnosis
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Treatment
      • 6.2.5.5.2. By Type
      • 6.2.5.5.3. By Diagnosis
      • 6.2.5.5.4. By End User
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Treatment
      • 6.2.5.6.2. By Type
      • 6.2.5.6.3. By Diagnosis
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Treatment
      • 6.2.5.7.2. By Type
      • 6.2.5.7.3. By Diagnosis
      • 6.2.5.7.4. By End User

7. Asia-Pacific Non-cystic Fibrosis Bronchiectasis Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Type
    • 7.2.3. By Diagnosis
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Treatment
      • 7.2.5.1.2. By Type
      • 7.2.5.1.3. By Diagnosis
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Treatment
      • 7.2.5.2.2. By Type
      • 7.2.5.2.3. By Diagnosis
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Treatment
      • 7.2.5.3.2. By Type
      • 7.2.5.3.3. By Diagnosis
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Treatment
      • 7.2.5.4.2. By Type
      • 7.2.5.4.3. By Diagnosis
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Treatment
      • 7.2.5.5.2. By Type
      • 7.2.5.5.3. By Diagnosis
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Treatment
      • 7.2.5.6.2. By Type
      • 7.2.5.6.3. By Diagnosis
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Treatment
      • 7.2.5.7.2. By Type
      • 7.2.5.7.3. By Diagnosis
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Treatment
      • 7.2.5.8.2. By Type
      • 7.2.5.8.3. By Diagnosis
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Treatment
      • 7.2.5.9.2. By Type
      • 7.2.5.9.3. By Diagnosis
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Treatment
      • 7.2.5.10.2. By Type
      • 7.2.5.10.3. By Diagnosis
      • 7.2.5.10.4. By End User
      • 7.2.5.11. Rest of APAC
      • 7.2.5.11.1. By Treatment
      • 7.2.5.11.2. By Type
      • 7.2.5.11.3. By Diagnosis
      • 7.2.5.11.4. By End User

8. Latin America Non-cystic Fibrosis Bronchiectasis Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Type
    • 8.2.3. By Diagnosis
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Treatment
      • 8.2.5.1.2. By Type
      • 8.2.5.1.3. By Diagnosis
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Treatment
      • 8.2.5.2.2. By Type
      • 8.2.5.2.3. By Diagnosis
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Treatment
      • 8.2.5.3.2. By Type
      • 8.2.5.3.3. By Diagnosis
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Treatment
      • 8.2.5.4.2. By Type
      • 8.2.5.4.3. By Diagnosis
      • 8.2.5.4.4. By End User
      • 8.2.5.4.5.
      • 8.2.5.5. Colombia
      • 8.2.5.5.1. By Treatment
      • 8.2.5.5.2. By Type
      • 8.2.5.5.3. By Diagnosis
      • 8.2.5.5.4. By End User
      • 8.2.5.6. Rest of LATAM
      • 8.2.5.6.1. By Treatment
      • 8.2.5.6.2. By Type
      • 8.2.5.6.3. By Diagnosis
      • 8.2.5.6.4. By End User

9. Middle East & Africa Non-cystic Fibrosis Bronchiectasis Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Type
    • 9.2.3. By Diagnosis
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Treatment
      • 9.2.5.1.2. By Type
      • 9.2.5.1.3. By Diagnosis
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Treatment
      • 9.2.5.2.2. By Type
      • 9.2.5.2.3. By Diagnosis
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Treatment
      • 9.2.5.3.2. By Type
      • 9.2.5.3.3. By Diagnosis
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Treatment
      • 9.2.5.4.2. By Type
      • 9.2.5.4.3. By Diagnosis
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Treatment
      • 9.2.5.5.2. By Type
      • 9.2.5.5.3. By Diagnosis
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Treatment
      • 9.2.5.6.2. By Type
      • 9.2.5.6.3. By Diagnosis
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Treatment
      • 9.2.5.7.2. By Type
      • 9.2.5.7.3. By Diagnosis
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Treatment
      • 9.2.5.8.2. By Type
      • 9.2.5.8.3. By Diagnosis
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Non-cystic Fibrosis Bronchiectasis Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Non-cystic Fibrosis Bronchiectasis Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

  • 12.1. Novartis AG
  • 12.2. Teva Pharmaceutical Industries Ltd.
  • 12.3. Mylan N.V.
  • 12.4. Pfizer Inc.
  • 12.5. GlaxoSmithKline plc
  • 12.6. AstraZeneca plc
  • 12.7. Boehringer Ingelheim GmbH
  • 12.8. Sunovion Pharmaceuticals Inc.
  • 12.9. Insmed Incorporated
  • 12.10. Bayer AG
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumption & Limitation